ClinicalTrials.gg
CompletedNCT00540514Updated Oct 29, 2019Results posted

Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung Cancer

A Phase 3 interventional study of Albumin-bound paclitaxel and Paclitaxel in Non-Small Cell Lung Carcinoma, sponsored by Celgene. Completed at 37 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-10-29.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,052
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 47 studies testing Albumin-Bound Paclitaxel in Carcinoma, Non-Small-Cell Lung — 8 open to participants now, 11 under way, 1 of them phase 3. Albumin-Bound Paclitaxel · Carcinoma, Non-Small-Cell Lung.

Enrollment
Largest of 47
1,052 · median 64
Started
2007
with 2 others
Phase 3
8 of 47
1 open now
Registered
6th of 47
by date
Lead sponsor
7 of 47
Celgene

Among the 47 studies testing Albumin-Bound Paclitaxel in Carcinoma, Non-Small-Cell Lung, this one has the largest enrollment, is one of 3 that started in 2007, is one of 8 in phase 3, and was the 6th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

8 of the 47 studies testing Albumin-Bound Paclitaxel in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About Albumin-Bound Paclitaxel

Albumin-Bound Paclitaxel: first FDA approval 2005 (ABRAXANE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies testing Albumin-Bound Paclitaxel in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The purpose of this study is to compare disease response of Albumin-bound paclitaxel (ABI-007) plus Carboplatin versus Taxol and Carboplatin as first-line therapy in patients with advanced non-small cell lung cancer (NSCLC).

03

Conditions studied

  • Non-Small Cell Lung Carcinoma

Keywords

  • Advanced Non-Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed stage IIIB or IV non-small cell lung cancer (NSCLC)
  • Male or non-pregnant and non-lactating female, and equal or greater than age 18

    • If a female patient is of , as evidence by regular menstrual periods, she must have a negative serum pregnancy test (beta human chorionic gonadotropin [βhCG]) documented within 72 hours of the first administration of study drug
    • If sexually active, the patient must agree to utilize considered adequate and appropriate by the investigator
  • No other current active
  • Radiographically-documented (defined by the presence of at least 1 radiographically documented measurable lesion)
  • Patients must have received no prior chemotherapy for the treatment of disease. chemotherapy permitted providing cytotoxic chemotherapy was completed 12 months prior to starting the study
  • Patient has the following blood counts at baseline:

    • (ANC) greater than or equal to 1.5x10\^9/L
    • greater than or equal to 100x10\^9/L
    • (Hgb) greater than or equal to 9 g/dL
  • Patient has the following blood chemistry levels at baseline:

    • (SGOT), alanine aminotransferase (SGPT) less than or equal to 2.5 x (ULN) or less than or equal to 5.0 x ULN if liver metastases;
    • Total less than or equal to ULN
    • Creatinine less than or equal to 1.5 mg/dL
  • Expected survival of greater than 12 weeks
  • (ECOG) performance status 0 or 1
  • Patient or his/her legally authorized representative or guardian has been informed about the nature of the study, and has agreed to participate in the study, and signed the form prior to participation in any study-related activities

Exclusion criteria

Exclusion Criteria:

  • Evidence of active , including . Prior evidence of brain metastasis permitted only if treated and stable and off therapy for greater than or equal to 1 month
  • The only evidence of disease is non-measurable
  • Patient has pre-existing peripheral neuropathy of Grade 2, 3, or 4 (per [CTCAE] Version 3).
  • Patient received radiotherapy in the last 4 weeks, except if to a non-target lesion only. Prior radiation to a target lesion is permitted only if there has been clear progression of the lesion since radiation was completed
  • Patient has a concurrent illness
  • Patient has received treatment with any drug within the previous 4 weeks
  • Patient has a history of allergy or to any of the study drugs
  • Patient has serious medical risk factors involving any of the major organ systems such that the investigator considers it unsafe for the patient to receive an experimental research drug
  • Patient is enrolled in any other clinical protocol or investigational trial that involves administration of experimental therapy and/or therapeutic devices.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,052 participants (actual)

Study arms

  • Experimental
    Albumin-bound paclitaxel + Carboplatin

    Participants received albumin-bound paclitaxel (ABRAXANE®) 100 mg/m\^2 administered as an intravenous infusion over 30 minutes on Days 1, 8, and 15 of each 21-day cycle. Carboplatin was given at an Area Under the Curve (AUC) = 6 mg\*min/mL on Day 1 only of each 21-day cycle, beginning immediately after the completion of albumin-bound paclitaxel administration. Participants could continue treatment at the investigator's discretion until disease progression, development of an unacceptable toxicity, or withdrawal of consent.

    Drug: Albumin-bound paclitaxel · Drug: Carboplatin

  • Active comparator
    Paclitaxel + Carboplatin

    Participants received 200 mg/m\^2 paclitaxel (Taxol®) administered by intravenous infusion followed by carboplatin at AUC = 6 mg\*min/mL on Day 1 of a 21 day cycle. Participants could continue treatment at the investigator's discretion until disease progression, development of an unacceptable toxicity, or withdrawal of consent.

    Drug: Paclitaxel · Drug: Carboplatin

Interventions

  • Administered by intravenous infusion.

    Also known as: ABI-007, ABRAXANE®, nab®-paclitaxel

  • Administered by intravenous infusion.

    Also known as: Taxol®

  • Administered by intravenous infusion. Dosing was based on the Calvert formula: carboplatin dose (mg) = (Target AUC) x (glomerular filtration rate \[GFR\] + 25). For the purposes of this protocol, the GFR is considered to be equivalent to creatinine clearance (calculated by the method of Cockcroft and Gault, 1976).

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved an Objective Confirmed Complete Response or Partial Response by Blinded Radiology Assessment

    Antitumor response was defined as the percentage of participants who achieved an objective response (Confirmed Response \[CR\] or Partial Response \[PR\]), confirmed by repeat assessments performed no less than 4 weeks after the criteria for response were first met. Response was based on the blinded radiological review using Response Evaluation Criteria in Solid Tumors (RECIST) response guidelines, Version 1.0. A complete response was defined as a disappearance of all target and non-target lesions and no new lesions. Partial response was defined as ≥ 30% decrease in the sum of the longest diameters (SLD) of target lesions, taking as reference the baseline SLD, and the persistence of one or more non-target lesions not qualifying for CR or Progressive Disease (the "unequivocal progression" of existing non-target lesion(s) or appearance of one or more new lesions).

    Time frame: Objective response was evaluated every 6 weeks until progression or new anti-cancer therapy initiation, up to 22 months.

Secondary outcomes

  1. Progression-free Survival by Blinded Radiology Assessment

    Progression free survival time was defined as the time from the day of randomization to the start of disease progression or death (any cause), whichever occurred first, based on the blinded radiological review response assessment. Progressive disease was defined as a ≥ 20% increase in the SLD of target lesions, taking as reference the nadir SLD recorded since the treatment started, or the presence of one or more new lesions, or the "unequivocal progression" of existing non-target lesion(s) or appearance of one or more new lesion(s). Participants who did not have disease progression or had not died were censored at the last visit they were documented as progression free. If palliative radiotherapy or surgery at lesion sites occurred, the participant was censored at the last date without documented progression prior to radiotherapy or surgery. In follow-up, participants who began new therapy prior to progression were censored at the last documented date as progression-free.

    Time frame: Assessed every 6 weeks until progression or death, up to 38 months

  2. Overall Participant Survival

    Overall survival was defined as the time from the day of randomization to participant death (due to any cause), as assessed by post study follow-up performed monthly for 6 months and every 3 months thereafter for 12 months. All participants who were lost to the follow-up prior to the end of the trial or who completed the 18 month follow up phase were censored at last known time the participant was alive.

    Time frame: Up to 38 months

  3. Percentage of Participants With Controlled Disease

    Controlled disease was defined as the percentage of participants with stable disease for ≥ 16 weeks or confirmed complete or partial overall response, based on blinded radiological assessment. Stable disease was defined as neither sufficient shrinkage of target lesions to qualify for Partial Response, nor sufficient increase to qualify for Progressive Disease, or the persistence of one or more non-target lesions not qualifying for Complete Response or Progressive Disease.

    Time frame: Assessed every 6 weeks, up to 22 months

  4. Duration of Response in Responding Patients

    Duration of response was assessed by progression free survival for participants who achieved a confirmed complete response or partial response based on blinded radiological assessment.

    Time frame: Assessed every 6 weeks, up to 38 months

  5. Number of Participants With Adverse Events (AEs)

    A Treatment-emergent AE was any AE that began or worsened in grade after the start of study drug through 30 days after the last dose of study drug or end of study whichever is later. Treatment related toxicity was one considered by the investigator to be possibly, probably or definitely related to study drug. AEs were graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0 on the following scale: Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life-threatening, Grade 5 = death. A serious adverse event (SAE) is any untoward medical occurrence at any dose that: is fatal or life-threatening; results in persistent or significant disability or incapacity; requires or prolongs in-patient hospitalization; is a congenital anomaly/birth defect in the offspring of a patient; and conditions not included in the above that may jeopardize the patient or may require intervention to prevent one of the outcomes listed above.

    Time frame: Up to 38 months

  6. Pharmacokinetic (PK) Parameters

    Time frame: Blood samples for PK analyses were taken during Cycle 1 at 0.25, 3.5 and 24 hours post-infusion.

  7. SPARC Status and Correlation With Overall Survival

    The expression and cellular distribution of Secreted Protein Acidic and Rich in cysteine (SPARC) in biopsies of lung tumor was examined by immunohistochemistry using a 2 antibody system by an approved central laboratory and analyzed by 2 pathologists. The following tissue components were scored: tumor cells, fibroblasts, inflammatory cells, acellular stroma/matrix, and blood vessels. To classify participants into "high-SPARC" and "low-SPARC" groups, an average z-score was calculated across variables and classified "high-SPARC" (average z-scores ≥0) and "low-SPARC" (average z-scores \<0) groups. SPARC status was then correlated with overall survival (the time from the day of randomization to participant death due to any cause).

    Time frame: Archival tissue samples were used for SPARC analysis. Survival was assessed for up to 38 months.

Other outcomes

  1. Percentage of Participants Who Achieved an Objective Confirmed Complete Response or Partial Response by Blinded Radiology Assessment, by Histology

    Antitumor response was defined as the percentage of participants who achieved an objective response (Confirmed Response \[CR\] or Partial Response \[PR\]), confirmed by repeat assessments performed no less than 4 weeks after the criteria for response were first met. Response was based on the blinded radiological review using Response Evaluation Criteria in Solid Tumors (RECIST) response guidelines, Version 1.0. A complete response was defined as a disappearance of all target and non-target lesions and no new lesions. Partial response was defined as ≥ 30% decrease in the sum of the longest diameters (SLD) of target lesions, taking as reference the baseline SLD, and the persistence of one or more non-target lesions not qualifying for CR or Progressive Disease (the "unequivocal progression" of existing non-target lesion(s) or appearance of one or more new lesions). Histology was determined at the time of primary diagnosis.

    Time frame: Objective response was evaluated every 6 weeks until progression or new anti-cancer therapy initiation, up to 22 months.

  2. Maximal Degree of Anemia Based on Clinical Laboratory Values for Hemoglobin

    The maximal degree of anemia (and myelosuppression) was assessed by the overall nadir of hemoglobin levels based on clinical laboratory measurements graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0.

    Time frame: 38 months

  3. Maximal Degree of Neutropenia Based on Clinical Laboratory Values of Absolute Neutrophil Count

    The maximal degree of neutropenia (and myelosuppression) was assessed by the overall nadir of absolute neutrophil count (ANC) based on clinical laboratory measurements graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0.

    Time frame: 38 months

  4. Maximal Degree of Thrombocytopenia Based on Clinical Laboratory Values of Platelet Count

    The maximal degree of thrombocytopenia (and myelosuppression) was assessed by the overall nadir of platelet count based on clinical laboratory measurements graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0.

    Time frame: 38 months

  5. Time to Improvement of ≥ Grade 3 Treatment Related Peripheral Neuropathy

    Peripheral neuropathy was graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 on the following scale: Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life-threatening, Grade 5 = death. Improvement in peripheral neuropathy was evaluated as: * Time to improvement of grade 3 or higher peripheral neuropathy by at least one grade; * Time to improvement of grade 3 or higher peripheral neuropathy to grade 1. Time to improvement was defined as the time from the first occurrence of grade 3 or higher treatment related neuropathy to improvement, as defined. Participants not experiencing improvement were censored at the last time the participant was evaluated for adverse events.

    Time frame: 38 months

07

Results

Posted Aug 19, 2013

Participant flow

Participant flow — Overall Study
MilestoneAlbumin-bound Paclitaxel + CarboplatinPaclitaxel + Carboplatin
Started521531
Treated514524
Biomarker population3536
Completed275265
Not completed246266
Withdrew: Still on treatment30
Withdrew: Unacceptable toxicity6162
Withdrew: Adverse event2024
Withdrew: Physician decision8699
Withdrew: Protocol deviation34
Withdrew: Lost to follow-up11
Withdrew: Withdrawal by subject6567
Withdrew: Excluded prior to treatment77
Withdrew: Paclitaxel not available02

Outcome measures

PrimaryPercentage of Participants Who Achieved an Objective Confirmed Complete Response or Partial Response by Blinded Radiology Assessment

Antitumor response was defined as the percentage of participants who achieved an objective response (Confirmed Response \[CR\] or Partial Response \[PR\]), confirmed by repeat assessments performed no less than 4 weeks after the criteria for response were first met. Response was based on the blinded radiological review using Response Evaluation Criteria in Solid Tumors (RECIST) response guidelines, Version 1.0. A complete response was defined as a disappearance of all target and non-target lesions and no new lesions. Partial response was defined as ≥ 30% decrease in the sum of the longest diameters (SLD) of target lesions, taking as reference the baseline SLD, and the persistence of one or more non-target lesions not qualifying for CR or Progressive Disease (the "unequivocal progression" of existing non-target lesion(s) or appearance of one or more new lesions).

Time frame:
Objective response was evaluated every 6 weeks until progression or new anti-cancer therapy initiation, up to 22 months.
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved an Objective Confirmed Complete Response or Partial Response by Blinded Radiology Assessment
percentage of participantsAlbumin-bound Paclitaxel + CarboplatinPaclitaxel + Carboplatin
Percentage of Participants Who Achieved an Objective Confirmed Complete Response or Partial Response by Blinded Radiology Assessment33 (28.6 to 36.7)25 (21.2 to 28.5)
Statistical analysis
  • Albumin-bound Paclitaxel + Carboplatin vs Paclitaxel + Carboplatin · Chi-squared · p = 0.005 (Statistical significance defined as P-value \< 0.049.) · Response rate ratio: 1.313 · 95.1% CI 1.082 to 1.593Response rate ratio = PA/PT. A response rate ratio \> 1 favors the albumin-bound paclitaxel/carboplatin arm of the study.
SecondaryProgression-free Survival by Blinded Radiology Assessment

Progression free survival time was defined as the time from the day of randomization to the start of disease progression or death (any cause), whichever occurred first, based on the blinded radiological review response assessment. Progressive disease was defined as a ≥ 20% increase in the SLD of target lesions, taking as reference the nadir SLD recorded since the treatment started, or the presence of one or more new lesions, or the "unequivocal progression" of existing non-target lesion(s) or appearance of one or more new lesion(s). Participants who did not have disease progression or had not died were censored at the last visit they were documented as progression free. If palliative radiotherapy or surgery at lesion sites occurred, the participant was censored at the last date without documented progression prior to radiotherapy or surgery. In follow-up, participants who began new therapy prior to progression were censored at the last documented date as progression-free.

Time frame:
Assessed every 6 weeks until progression or death, up to 38 months
Reported as:
Median · months
Progression-free Survival by Blinded Radiology Assessment
monthsAlbumin-bound Paclitaxel + CarboplatinPaclitaxel + Carboplatin
Progression-free Survival by Blinded Radiology Assessment6.3 (5.6 to 7.0)5.8 (5.6 to 6.7)
Statistical analysis
  • Albumin-bound Paclitaxel + Carboplatin vs Paclitaxel + Carboplatin · Log Rank · p = 0.214 (P-value is based on a stratified log rank test stratified by geographic region (North America/Australia, Eastern Europe, or Asia/Pacific) and histology of primary diagnosis (squamous cell carcinoma, adenocarcinoma, or other carcinoma).) · Hazard ratio (hr): 0.902 · 95.1% CI 0.767 to 1.060Hazard ratio (albumin-bound paclitaxel/carboplatin to paclitaxel/carboplatin) \<1 favors the albumin-bound paclitaxel/carboplatin group.
SecondaryOverall Participant Survival

Overall survival was defined as the time from the day of randomization to participant death (due to any cause), as assessed by post study follow-up performed monthly for 6 months and every 3 months thereafter for 12 months. All participants who were lost to the follow-up prior to the end of the trial or who completed the 18 month follow up phase were censored at last known time the participant was alive.

Time frame:
Up to 38 months
Reported as:
Median · months
Overall Participant Survival
monthsAlbumin-bound Paclitaxel + CarboplatinPaclitaxel + Carboplatin
Overall Participant Survival12.1 (10.8 to 12.9)11.2 (10.3 to 12.6)
Statistical analysis
  • Albumin-bound Paclitaxel + Carboplatin vs Paclitaxel + Carboplatin · Log Rank · p = 0.271 (P-value is based on a stratified log rank test stratified by geographic region (North America/Australia, Eastern Europe, or Asia/Pacific) and histology of primary diagnosis (Squamous cell carcinoma, adenocarcinoma, or other carcinoma).) · Hazard ratio (hr): 0.922 · 95.1% CI 0.797 to 1.066Hazard ratio (albumin-bound paclitaxel/carboplatin to paclitaxel/carboplatin) \<1 favors the albumin-bound paclitaxel/carboplatin group.
SecondaryPercentage of Participants With Controlled Disease

Controlled disease was defined as the percentage of participants with stable disease for ≥ 16 weeks or confirmed complete or partial overall response, based on blinded radiological assessment. Stable disease was defined as neither sufficient shrinkage of target lesions to qualify for Partial Response, nor sufficient increase to qualify for Progressive Disease, or the persistence of one or more non-target lesions not qualifying for Complete Response or Progressive Disease.

Time frame:
Assessed every 6 weeks, up to 22 months
Reported as:
Number · percentage of participants
Percentage of Participants With Controlled Disease
percentage of participantsAlbumin-bound Paclitaxel + CarboplatinPaclitaxel + Carboplatin
Percentage of Participants With Controlled Disease53 (48.3 to 56.9)49 (44.7 to 53.2)
Statistical analysis
  • Albumin-bound Paclitaxel + Carboplatin vs Paclitaxel + Carboplatin · Chi-squared · p = 0.239 · Response rate ratio: 1.074 · 95% CI 0.953 to 1.210
SecondaryDuration of Response in Responding Patients

Duration of response was assessed by progression free survival for participants who achieved a confirmed complete response or partial response based on blinded radiological assessment.

Time frame:
Assessed every 6 weeks, up to 38 months
Reported as:
Median · months
Duration of Response in Responding Patients
monthsAlbumin-bound Paclitaxel + CarboplatinPaclitaxel + Carboplatin
Duration of Response in Responding Patients9.6 (8.3 to 10.8)9.5 (8.1 to 11.0)
Statistical analysis
  • Albumin-bound Paclitaxel + Carboplatin vs Paclitaxel + Carboplatin · Log Rank · p = 0.551 (P-value is based on a stratified log rank test stratified by geographic region (North America/Australia, Eastern Europe, or Asia/Pacific) and histology of primary diagnosis (Squamous cell carcinoma or Non squamous cell carcinoma).) · Hazard ratio (hr): 0.901 · 95% CI 0.652 to 1.244Hazard ratio (albumin-bound paclitaxel/carboplatin to paclitaxel/carboplatin) \<1 favors the albumin-bound paclitaxel/carboplatin group.
SecondaryNumber of Participants With Adverse Events (AEs)

A Treatment-emergent AE was any AE that began or worsened in grade after the start of study drug through 30 days after the last dose of study drug or end of study whichever is later. Treatment related toxicity was one considered by the investigator to be possibly, probably or definitely related to study drug. AEs were graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0 on the following scale: Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life-threatening, Grade 5 = death. A serious adverse event (SAE) is any untoward medical occurrence at any dose that: is fatal or life-threatening; results in persistent or significant disability or incapacity; requires or prolongs in-patient hospitalization; is a congenital anomaly/birth defect in the offspring of a patient; and conditions not included in the above that may jeopardize the patient or may require intervention to prevent one of the outcomes listed above.

Time frame:
Up to 38 months
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs)
participantsAlbumin-bound Paclitaxel + CarboplatinPaclitaxel + Carboplatin
At least 1 AE483504
At least 1 grade 3 or higher AE360355
At least 1 treatment-related AE469481
At least 1 treatment-related grade 3 or higher AE321315
At least 1 serious AE9380
At least 1 treatment-related serious AE3730
At least 1 AE with taxane permanently discontinued8084
At least 1 AE with action of taxane dosage reduced237120
At least 1 AE with action of taxane interrupted05
At least 1 AE with action of taxane delayed365214
SecondaryPharmacokinetic (PK) Parameters
Time frame:
Blood samples for PK analyses were taken during Cycle 1 at 0.25, 3.5 and 24 hours post-infusion.

No measurements were reported for this outcome.

SecondarySPARC Status and Correlation With Overall Survival

The expression and cellular distribution of Secreted Protein Acidic and Rich in cysteine (SPARC) in biopsies of lung tumor was examined by immunohistochemistry using a 2 antibody system by an approved central laboratory and analyzed by 2 pathologists. The following tissue components were scored: tumor cells, fibroblasts, inflammatory cells, acellular stroma/matrix, and blood vessels. To classify participants into "high-SPARC" and "low-SPARC" groups, an average z-score was calculated across variables and classified "high-SPARC" (average z-scores ≥0) and "low-SPARC" (average z-scores \<0) groups. SPARC status was then correlated with overall survival (the time from the day of randomization to participant death due to any cause).

Time frame:
Archival tissue samples were used for SPARC analysis. Survival was assessed for up to 38 months.
Reported as:
Number · participants
SPARC Status and Correlation With Overall Survival
participantsAlbumin-bound Paclitaxel + CarboplatinPaclitaxel + Carboplatin
High-SPARC17 (3.3 to 23.1)22 (2.3 to 28.0)
Low-SPARC18 (3.7 to 24.9)14 (4.7 to 22.3)
Statistical analysis
  • Albumin-bound Paclitaxel + Carboplatin vs Paclitaxel + Carboplatin · Univariate Cox regression · p = 0.302
Other pre-specifiedPercentage of Participants Who Achieved an Objective Confirmed Complete Response or Partial Response by Blinded Radiology Assessment, by Histology

Antitumor response was defined as the percentage of participants who achieved an objective response (Confirmed Response \[CR\] or Partial Response \[PR\]), confirmed by repeat assessments performed no less than 4 weeks after the criteria for response were first met. Response was based on the blinded radiological review using Response Evaluation Criteria in Solid Tumors (RECIST) response guidelines, Version 1.0. A complete response was defined as a disappearance of all target and non-target lesions and no new lesions. Partial response was defined as ≥ 30% decrease in the sum of the longest diameters (SLD) of target lesions, taking as reference the baseline SLD, and the persistence of one or more non-target lesions not qualifying for CR or Progressive Disease (the "unequivocal progression" of existing non-target lesion(s) or appearance of one or more new lesions). Histology was determined at the time of primary diagnosis.

Time frame:
Objective response was evaluated every 6 weeks until progression or new anti-cancer therapy initiation, up to 22 months.
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved an Objective Confirmed Complete Response or Partial Response by Blinded Radiology Assessment, by Histology
percentage of participantsAlbumin-bound Paclitaxel + CarboplatinPaclitaxel + Carboplatin
Carcinoma/Adenocarcinoma [254, 264]2627
Squamous Cell Carcinoma [229, 221]4124
Large Cell Carcinoma [N=9, 13]3315
Other [N=29, 33]2415
Statistical analysis
  • Albumin-bound Paclitaxel + Carboplatin · Regression, Logistic · p = 0.036 (A nonsignificant interaction P-value (ie, p-value ≥ 0.100) indicates the treatment regimen effect was consistent within a prognostic factor.)Logistic regression model with effects for treatment regimen, prognostic factor (histology), and treatment regimen by prognostic factor interaction.
Other pre-specifiedMaximal Degree of Anemia Based on Clinical Laboratory Values for Hemoglobin

The maximal degree of anemia (and myelosuppression) was assessed by the overall nadir of hemoglobin levels based on clinical laboratory measurements graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0.

Time frame:
38 months
Reported as:
Mean · g/L
Maximal Degree of Anemia Based on Clinical Laboratory Values for Hemoglobin
g/LAlbumin-bound Paclitaxel + CarboplatinPaclitaxel + Carboplatin
Maximal Degree of Anemia Based on Clinical Laboratory Values for Hemoglobin90.0 ± 17.19103.9 ± 16.90
Other pre-specifiedMaximal Degree of Neutropenia Based on Clinical Laboratory Values of Absolute Neutrophil Count

The maximal degree of neutropenia (and myelosuppression) was assessed by the overall nadir of absolute neutrophil count (ANC) based on clinical laboratory measurements graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0.

Time frame:
38 months
Reported as:
Mean · × 10^9/L
Maximal Degree of Neutropenia Based on Clinical Laboratory Values of Absolute Neutrophil Count
× 10^9/LAlbumin-bound Paclitaxel + CarboplatinPaclitaxel + Carboplatin
Maximal Degree of Neutropenia Based on Clinical Laboratory Values of Absolute Neutrophil Count1.39 ± 1.7211.26 ± 1.366
Other pre-specifiedMaximal Degree of Thrombocytopenia Based on Clinical Laboratory Values of Platelet Count

The maximal degree of thrombocytopenia (and myelosuppression) was assessed by the overall nadir of platelet count based on clinical laboratory measurements graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0.

Time frame:
38 months
Reported as:
Mean · × 10^9/L
Maximal Degree of Thrombocytopenia Based on Clinical Laboratory Values of Platelet Count
× 10^9/LAlbumin-bound Paclitaxel + CarboplatinPaclitaxel + Carboplatin
Maximal Degree of Thrombocytopenia Based on Clinical Laboratory Values of Platelet Count114.9 ± 82.13136.6 ± 81.91
Other pre-specifiedTime to Improvement of ≥ Grade 3 Treatment Related Peripheral Neuropathy

Peripheral neuropathy was graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 on the following scale: Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life-threatening, Grade 5 = death. Improvement in peripheral neuropathy was evaluated as: * Time to improvement of grade 3 or higher peripheral neuropathy by at least one grade; * Time to improvement of grade 3 or higher peripheral neuropathy to grade 1. Time to improvement was defined as the time from the first occurrence of grade 3 or higher treatment related neuropathy to improvement, as defined. Participants not experiencing improvement were censored at the last time the participant was evaluated for adverse events.

Time frame:
38 months
Reported as:
Median · days
Time to Improvement of ≥ Grade 3 Treatment Related Peripheral Neuropathy
daysAlbumin-bound Paclitaxel + CarboplatinPaclitaxel + Carboplatin
Improvement by ≥1 grade24.0 (15.0 to NA)26.0 (15.0 to 38.0)
Improvement to grade 138.0 (19.0 to NA)104.0 (40.0 to 169.0)

Adverse events

Collected over Up to 38 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Albumin-bound Paclitaxel + Carboplatin—93/514 (18.1%)483/514 (94%)
Paclitaxel + Carboplatin—80/524 (15.3%)499/524 (95.2%)
Most frequent serious events
Showing 10 of 91
Most frequent serious events
EventAlbumin-bound Paclitaxel + CarboplatinPaclitaxel + Carboplatin
AnaemiaBlood and lymphatic system disorders19/5143/524
PneumoniaInfections and infestations14/51411/524
Pulmonary embolismRespiratory, thoracic and mediastinal disorders4/5148/524
DyspnoeaRespiratory, thoracic and mediastinal disorders4/5146/524
Febrile neutropeniaBlood and lymphatic system disorders4/5145/524
Pulmonary haemorrhageRespiratory, thoracic and mediastinal disorders3/5144/524
Pleural effusionRespiratory, thoracic and mediastinal disorders1/5143/524
HaemoptysisRespiratory, thoracic and mediastinal disorders2/5141/524
PneumothoraxRespiratory, thoracic and mediastinal disorders2/5141/524
Cerebral infarctionNervous system disorders2/5140/524
Most frequent other events
Showing 10 of 37
Most frequent other events
EventAlbumin-bound Paclitaxel + CarboplatinPaclitaxel + Carboplatin
AlopeciaSkin and subcutaneous tissue disorders287/514312/524
NeutropeniaBlood and lymphatic system disorders260/514250/524
AnaemiaBlood and lymphatic system disorders225/514109/524
ThrombocytopeniaBlood and lymphatic system disorders208/514122/524
Peripheral sensory neuropathyNervous system disorders136/514209/524
NauseaGastrointestinal disorders140/514130/524
ArthralgiaMusculoskeletal and connective tissue disorders65/514129/524
FatigueGeneral disorders126/514120/524
Neuropathy peripheralNervous system disorders104/514118/524
LeukopeniaBlood and lymphatic system disorders97/51491/524

Baseline characteristics

Age, Continuous
Age, Continuous(years)Albumin-bound Paclitaxel + CarboplatinPaclitaxel + CarboplatinTotal
Mean59.5 ± 9.1459.7 ± 9.5359.6 ± 9.33
Sex: Female, Male
Sex: Female, Male(Participants)Albumin-bound Paclitaxel + CarboplatinPaclitaxel + CarboplatinTotal
Female129134263
Male392397789
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Albumin-bound Paclitaxel + CarboplatinPaclitaxel + CarboplatinTotal
Asian7980159
Black, of African Heritage12820
North American Indian or Alaska Native101
White, Non Hispanic and Non Latino416433849
White, Hispanic or Latino11516
Other257
Region of Enrollment
Region of Enrollment(participants)Albumin-bound Paclitaxel + CarboplatinPaclitaxel + CarboplatinTotal
United States6358121
Canada212344
Australia5914
Japan7475149
Russian Federation238231469
Ukraine120135255
Smoking status
Smoking status(participants)Albumin-bound Paclitaxel + CarboplatinPaclitaxel + CarboplatinTotal
Never smoked137144281
Smoked and quit smoking168148316
Smoked and currently smokes214234448
Missing257
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(participants)Albumin-bound Paclitaxel + CarboplatinPaclitaxel + CarboplatinTotal
0 (Fully active)133113246
1 (Restrictive but ambulatory)385416801
2 (Ambulatory but unable to work)325
Time from Primary Diagnosis to Study Entry
Time from Primary Diagnosis to Study Entry(months)Albumin-bound Paclitaxel + CarboplatinPaclitaxel + CarboplatinTotal
Mean4.3 ± 17.124.3 ± 16.094.3 ± 16.60
Stage at Primary Diagnosis
Stage at Primary Diagnosis(participants)Albumin-bound Paclitaxel + CarboplatinPaclitaxel + CarboplatinTotal
I162036
II182442
IIIa222446
IIIb135116251
IV325344669
Unknown538

4 further baseline measures are reported on the registry.

08

Study locations

37 sites
  • Clearview Cancer Institute Oncology Specialties, P.C.
    Huntsville, Alabama 35805, United States
  • Genesis Cancer Center- Hot Springs
    Hot Springs, Arkansas 71913, United States
  • Little Rock Hematology Oncology Associates
    Little Rock, Arkansas 72205, United States
  • Pacific Cancer Medical Center, Inc.
    Anaheim, California 92801, United States
  • Comprehensive Blood and Cancer Center
    Bakersfield, California 93309, United States
  • Southwest Cancer Care
    Escondido, California 92064, United States
  • Robert A. Moss, MD, FACP, Inc.
    Fountain Valley, California 92708, United States
  • Pacific Shores Medical Group
    Long Beach, California 90813, United States
  • Ventura County Hematology-Oncology Specialists
    Oxnard, California 93030, United States
  • Comprehensice Cancer Ctr.
    Palms Springs, California 92262, United States
  • Gulf Coast Oncology Associates
    Saint Petersburg, Florida 33705, United States
  • Lake County Oncology and Hematology, PA
    Tavares, Florida 32778, United States
  • Phoebe Cancer Center
    Albany, Georgia 31701, United States
  • Cancer Center of Kansas
    Wichita, Kansas 67214, United States
  • Kentuckiana Cancer Institute, PLLC
    Louisville, Kentucky 40202, United States
  • Mercy Hospital
    Portland, Maine 04101, United States
  • Maine Center for Cancer Medicine
    Scarborough, Maine 04074, United States
  • Mercy Medical Center
    Baltimore, Maryland 21202, United States
  • St. Louis University
    Saint Louis, Missouri 63110, United States
  • Essex Oncology of North Jersey
    Belleville, New Jersey 07109, United States
  • Mary Imogene Bassett Hospital
    Cooperstown, New York 13326, United States
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27599, United States
  • St. Mary Medical Center- Oncology, Hematology PC
    Langhorne, Pennsylvania 19047, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Dallas Oncology Consultants, PA
    Duncanville, Texas 75137, United States
  • The Center for Cancers and Blood Disorders
    Fort Worth, Texas 76104, United States
  • Joe Arrington Cancer Research and Treatment Center
    Lubbock, Texas 79410, United States
  • Blood and Cancer Center of East Texas
    Tyler, Texas 75701, United States
  • Tyler Hematology Oncology
    Tyler, Texas 75701, United States
  • Fletcher Allen Health Care
    Burlington, Vermont 05405, United States
  • Cancer Outreach Associates, PC
    Abingdon, Virginia 24211, United States
  • Royal Columbian Hospital
    New Westminster, British Columbia V3L 3W4, Canada
  • William Osler Health Centre, Brampton Clinic
    Brampton, Ontario L6R 3J7, Canada
  • Toronto East General Hospital
    Toronto, Ontario M4C3E7, Canada
  • Princess Margaret Hospital
    Toronto, Ontario M5G 2M9, Canada
  • McGill University- Dept. of Oncology
    Montreal, Quebec H2W 1S6, Canada
  • Hopital du Sacre-Coeur de Montreal
    Montreal, Quebec H4J 1C5, Canada
09

References and documents

Publications

  • Hirsh V. nab-paclitaxel for the management of patients with advanced non-small-cell lung cancer. Expert Rev Anticancer Ther. 2014 Feb;14(2):129-41. doi: 10.1586/14737140.2014.881719. PubMed 24467217 ↗
  • Langer CJ, Hirsh V, Ko A, Renschler MF, Socinski MA. Weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: analysis of safety and efficacy in patients with renal impairment. Clin Lung Cancer. 2015 Mar;16(2):112-20. doi: 10.1016/j.cllc.2014.09.003. Epub 2014 Sep 30. PubMed 25572008 ↗
  • Langer CJ, Hirsh V, Okamoto I, Lin FJ, Wan Y, Whiting S, Ong TJ, Renschler MF, Botteman MF. Survival, quality-adjusted survival, and other clinical end points in older advanced non-small-cell lung cancer patients treated with albumin-bound paclitaxel. Br J Cancer. 2015 Jun 30;113(1):20-9. doi: 10.1038/bjc.2015.181. Epub 2015 Jun 2. PubMed 26035702 ↗
  • Socinski MA, Bondarenko I, Karaseva NA, Makhson AM, Vynnychenko I, Okamoto I, Hon JK, Hirsh V, Bhar P, Zhang H, Iglesias JL, Renschler MF. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol. 2012 Jun 10;30(17):2055-62. doi: 10.1200/JCO.2011.39.5848. Epub 2012 Apr 30. PubMed 22547591 ↗
  • Socinski MA, Langer CJ, Okamoto I, Hon JK, Hirsh V, Dakhil SR, Page RD, Orsini J, Zhang H, Renschler MF. Safety and efficacy of weekly nab(R)-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer. Ann Oncol. 2013 Feb;24(2):314-321. doi: 10.1093/annonc/mds461. Epub 2012 Nov 2. PubMed 23123509 ↗
  • Satouchi M, Okamoto I, Sakai H, Yamamoto N, Ichinose Y, Ohmatsu H, Nogami N, Takeda K, Mitsudomi T, Kasahara K, Negoro S. Efficacy and safety of weekly nab-paclitaxel plus carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer. 2013 Jul;81(1):97-101. doi: 10.1016/j.lungcan.2013.02.020. Epub 2013 Mar 30. PubMed 23545279 ↗
  • Socinski MA, Okamoto I, Hon JK, Hirsh V, Dakhil SR, Page RD, Orsini J, Yamamoto N, Zhang H, Renschler MF. Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer. Ann Oncol. 2013 Sep;24(9):2390-6. doi: 10.1093/annonc/mdt235. Epub 2013 Jul 10. PubMed 23842283 ↗
  • Hirsh V, Okamoto I, Hon JK, Page RD, Orsini J, Sakai H, Zhang H, Renschler MF, Socinski MA. Patient-reported neuropathy and taxane-associated symptoms in a phase 3 trial of nab-paclitaxel plus carboplatin versus solvent-based paclitaxel plus carboplatin for advanced non-small-cell lung cancer. J Thorac Oncol. 2014 Jan;9(1):83-90. doi: 10.1097/JTO.0000000000000011. PubMed 24346096 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2007 to primary completion in Oct 2009, 23 months.

Results were first posted in Aug 2013, 3 years 10 months after primary completion.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 23 months is below that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2007
First posted
Oct 8, 2007
StartActual
Nov 1, 2007
Primary completionActual
Oct 1, 2009
CompletionActual
Feb 1, 2013
Results first posted
Aug 19, 2013
Last update
Oct 29, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 29, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00540514
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Oct 8, 2007
Start date
Nov 1, 2007
Primary completion
Oct 1, 2009
Completion
Feb 1, 2013
Results posted
Aug 19, 2013
Last update
Oct 29, 2019

Study contacts

Mark A Socinski, MD
principal investigator · University of North Carolina, Chapel Hill

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Albumin-Bound Paclitaxel

Start the discussion